Quintrio
Home

ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES

STERIS plc

STE

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.

Last trade $257.98
Day change -$3.93 (-1.50%)
Day range $257.36 – $262.39
Volume 288,017
Market cap $25.43B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$25.43B
Price / earnings
30.76×
Price / book
3.5×
Price / sales
4.12×
EV / sales
4.35×
EV / EBITDA
15.89×

Profitability

Earnings per share
$8.52
Return on assets
7.72%
Return on equity
11.39%
Dividend yield
0.99%

Liquidity and leverage

Debt / equity
0.26×
Current ratio
2.05×
Quick ratio
1.44×
Cash ratio
0.44×

Cash flow

Price / cash flow
19.72×
Price / free cash flow
27.13×
Free cash flow
$937.3M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for STE, quarterly periods
Line itemQ2 FY2027 Sep 30, 2026Q1 FY2027 Jun 30, 2026Q4 FY2026 Mar 31, 2026Q3 FY2026 Dec 31, 2025Q2 FY2026 Sep 30, 2025Q1 FY2026 Jun 30, 2025Q4 FY2025 Mar 31, 2025Q3 FY2025 Dec 31, 2024
Revenue$1.59B$1.49B$1.59B$1.5B$1.46B$1.39B$1.48B$1.37B
Cost of revenue$877.7M$808.5M$891.2M$840.7M$814.4M$763.1M$839.3M$760.2M
Gross profit$710.9M$684.2M$697.2M$655.5M$645.9M$628M$641.2M$610.4M
Selling, general and administrative$366M$369.7M$351.8M$352.3M$349.7M$353.8M$333.9M$335.5M
Research and development$31.5M$28.6M$28.8M$29.5M$28.2M$26.4M$27.6M$27.4M
Total operating expenses$415.3M$398M$380.3M$382.2M$380.3M$382M$425M$365.1M
Operating income$295.6M$286.2M$316.9M$273.3M$265.6M$246M$216.2M$245.3M
Interest expense-$11.2M-$15.8M-$15.1M-$14.9M-$14.9M-$15.9M-$17.2M-$19.1M
Income before taxes$288M$273.5M$304.5M$258M$253.1M$231.9M$197.3M$228.7M
Income taxes$73.9M$72.5M$84.2M$63.5M$60.6M$53.9M$50.5M$55.4M
Net income$214.1M$201M$220.3M$194.5M$192.5M$178M$146M$173.2M
Net income attributable to common shareholders$213.7M$200.1M$220.2M$192.9M$191.9M$177.4M$145.6M$173.5M
EBITDA$440.3M$410M$440M$395.7M$389.5M$367.2M$353.8M$373.4M
Basic earnings per share$2.20$2.05$2.25$1.96$1.95$1.80$1.49$1.76
Diluted earnings per share$2.19$2.04$2.23$1.96$1.94$1.79$1.47$1.75

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics

Steris reported Q2 2026 revenue of $1.59 billion, up 8.8% year-over-year, beating the consensus estimate of $1.56 billion by 1.54%. EPS came in at $2.94, exceeding the estimate of $2.67 by 10.11%. The company showed strong performance across most segments, with Life Sciences revenue up 17.7% and Healthcare Products-Consumables up 10.1%. Steris stock has gained 10.9% over the past month and holds a Zacks Rank #2 (Buy) rating.

Zacks Investment Research

Steris (STE) Q2 Earnings and Revenues Surpass Estimates

Steris reported quarterly earnings of $2.94 per share, beating consensus estimates of $2.67 and surpassing year-ago earnings of $2.47. The company also exceeded revenue expectations with $1.59 billion versus consensus of $1.56 billion. Despite strong earnings performance, Steris shares have underperformed the S&P 500 by 19.3% year-to-date. The stock holds a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.

Zacks Investment Research

STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock?

STERIS is expected to report Q2 fiscal 2027 revenues of $1.56 billion (up 7.1%) and EPS of $2.67 (up 8.1%) on November 4, 2026. The Healthcare segment should benefit from steady demand and recent acquisitions, while AST faces destocking headwinds. Life Sciences demand and pricing actions are expected to support margins. However, the Zacks model does not predict an earnings beat due to 0.00% Earnings ESP despite a Rank #2 rating.

Zacks Investment Research

Reasons to Add STE Stock to Your Portfolio Right Now

STERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth.

GlobeNewswire Inc.

STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety

STERIS plc announced a definitive agreement to acquire Xodus Medical, a specialty surgical products company, for $2.1 billion (net purchase price ~$1.8 billion after tax benefits). The acquisition is expected to close by December 31, 2026, and includes potential earnout consideration up to $150 million. Xodus Medical generated approximately $245 million in annual revenue for 2026 with $135 million in adjusted EBIT. STERIS expects the transaction to be accretive to top-line growth, margins, and adjusted earnings.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.69 per share
Declared
Oct 28, 2026
Ex-dividend
Nov 17, 2026
Pay date
Dec 17, 2026
Ex-dividendAmount / sharePay dateType
Sep 4, 2026$0.69Sep 25, 2026recurring
Jun 8, 2026$0.63Jun 26, 2026recurring
Feb 17, 2026$0.63Mar 19, 2026recurring
Nov 18, 2025$0.63Dec 18, 2025recurring
Sep 4, 2025$0.63Sep 26, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.